Alimta

... Millennium Reports Positive Data for VELCADE(R) (bortezomib) for Injection in Lymphoma and Lung Cancer at ASCO; Advances in MLN2704 Also Presented Millennium Reports Positive Data for VELCADE(R) (bortezomib) for Injection in Lymphoma and Lung Cancer at ASCO; Advances in MLN2704 Also Presented Results support broad development program and underscore strength of oncology pipeline ORLANDO, Fla., May 14 /PRNewswire-FirstCall/ - Millennium Pharmaceuticals, Inc.

(Nasdaq: MLNM) today announced positive results from studies of VELCADE in lymphoma and lung cancer at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place this week in Orlando, Florida.

Data for MLN2704, the Company's drug candidate for prostate cancer, were also presented.

Results included: * In relapsed patients with mantle cell lymphoma (MCL), interim results of a multicenter phase II study of single-agent VELCADE showed median survival had not been reached after 10.5 months of follow-up, and demonstrated an overall response rate of 42 percent; * In non-small cell lung cancer (NSCLC), final data from the single-agent arm of the multicenter phase II trial of VELCADE with or without docetaxel showed a response rate and overall survival comparable to approved agents for use in second-line lung cancer; and * In patients with late-stage, hormone-refractory prostate cancer, interim phase I/II results of MLN2704 showed four of six patients receiving a high dose ...

... mysan.de - be updated - Finalists Announced For the Fourth Annual Pharmaceutical Achievement Awards Web mysan.de Auto Computer Film Games Handy Heidelberg Internet Musik News Aktuell PRNewsWire Sport Stars TV Verschiedenes Wirtschaft Menu MSGI Security Solutions Hosts I.A.C.P.

Anti-Terr...

... Lilly, Roche developing tests to match patients, cancer drugs MARKETPLACE: Classifieds Dana Knight AP Business AP Technology Sports Entertainment Indiana Living Obituaries Weather | Traffic CustomerServices SubscriberServices INtake Communities Fact Files MessageBoards Multimedia/Photos Newsletters Star Links Links mentionedin The Star Star Source Send us yournews tips, ideas Cyber survey Should high schools prohibit students from wearing sexy attire at proms?

Yes No 7 days Archive May 11, 2005 Lilly, Roche developing tests to match patients, cancer drugs Indianapolis (Bloomberg) - Roche Holding AG, the biggest maker of cancer drugs and diagnostic tests, will work with Indianapolis-based drugmaker Eli Lilly and Co.

to develop tests to measure which patients will benefit from two cancer drugs.The tests may help identify which patients are most likely to respond to Lilly's The two companies will work with privately held Response Genetics Inc.

on the "biomarker" tests."This agreement is excellent news for both physicians and patients as the world of truly personalized medicine becomes an ever-growing reality," said Heino von Prondzynski, head of Roche's diagnostic divi...